Jak/stat pathway in Waldenström's macroglobulinemia

Lucy S. Hodge, Stephen M. Ansell

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


While high serum concentrations of immunoglobulin M (IgM) protein are responsible for much of the morbidity associated with Waldenström's macroglobulinemia (WM), the mechanisms controlling IgM secretion in this malignancy remain unknown. The Jak/Stat signaling pathway mediates the effects of most cytokines involved in stimulating immunoglobulin production in nonmalignant B cells. However, in many hematopoietic malignancies, cytokine-driven stimulation of the Jak/Stat pathway is hyperactive, promoting the expression of genes associated with proliferation and survival. Autocrine/paracrine signaling of cytokines present in the tumor microenvironment may lead to persistent Jak/Stat signal transduction in WM as well. Yet despite evidence implicating the Jak/Stat pathway in the pathogenesis of WM, the relationship between Jak/Stat-mediated cytokine signaling and IgM hypersecretion has not been defined. Through the use of targeted Jak/Stat inhibitors, it is now possible to examine the contribution of aberrant cytokine signaling to IgM production, potentially allowing for a more targeted approach to WM therapy.

Original languageEnglish (US)
Pages (from-to)112-114
Number of pages3
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number1
StatePublished - Feb 1 2011

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Jak/stat pathway in Waldenström's macroglobulinemia'. Together they form a unique fingerprint.

Cite this